Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows

Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows
The small molecule inhibitor SM07883, being developed by Samumed, can effectively prevent tau protein toxic accumulation, and tau-mediated neuroinflammation in mice, data from preclinical studies show. As tau-associated mechanisms are implicated in Alzheimer’s disease, these findings suggest that SM07883 may represent a new strategy for the treatment of this progressive neurodegenerative disorder. SM07883’s preclinical data was reported in the study “Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer’s disease,” published in the journal Aging Cell. A hallmark feature of Alzheimer’s is the accumulation of tau protein clumps in the brain. These accumulations are believed to precede the loss of nerve cells, shrinkage of the brain, and cognitive impairment that characterize this disease. SM07883 was engineered to effectively cross the blood-brain barrier, and specifically block the activity of the tyros
Subscribe or to access all post and page content.